Pfizer Begins Late-Stage Trial Testing Lyme Disease Vaccine

August 8, 2022

(NBC News) – Pfizer has started a late-stage clinical trial to test a vaccine that aims to protect against Lyme disease, the drugmaker announced Monday. There are currently no vaccines approved in the United States for the tick-borne illness, which infects an estimated 476,000 people in the U.S. each year, according to the Centers for Disease Control and Prevention. If Pfizer’s trial succeeds, the vaccine could be the first human inoculation available for Lyme disease in the U.S. in two decades. Only one other vaccine for the disease, LYMErix, has been used in the country, but it was discontinued in 2002.  (Read More)